Diabetes Flashcards
8 pharma approaches to diabetes
Metformin Sulfonylureas TZDs Meglitinides Alpha-Glucosidase inhibitors DPP-4 inhibitors GLP-1 agonists Insulin
MOA of Metformin
Decreases hepatic glucose production
Decreases intestinal glucose absorption
Improves insulin sensitivity
Metformin ADRs
Diarrhea, nausea, vomiting
Weight neutral or loss
Lactic acidosis
HOLD PRIOR TO IV CONTRAST UNTIL 48 HOURS WHEN RENAL FUNCTION HAS BEEN CONFIRMED AS NORMAL
MOA of Sulfonylureas
Stimulate insulin secretion
3 Sulfonylureas
Glipizide
Glimepiride
Glyburide
Sulfonylureas ADRs
Watch for sulfa allergy
Can cause hypoglycemia
Weight gain
MOA of Meglitinides
Stimulate insulin secretion
don’t use with sulfonylureas, same MOA
2 Meglitinides
Repaglinide
Nateglinide
ADRs of Meglitinides
Hypoglycemia
Weight gain
MOA of TZDs
Increases peripheral insulin sensitivity
2 TZDs
Pioglitazone
Roziglitazone
ADRs of TZDs
Avoid in advance heart failure
Avoid in pts with active or history of bladder cancer
Cause edema
Weight gain
MOA of Alpha-Glucosidase Inhibitors
Delays absorption of glucose
ADRs of Alpha-Glucosidase inhibitors
GI side effects
MOA of DPP-4 Inhibitors
Increase insulin release
Decrease glucagon release
Reduction in hepatic glucose production